Bausch + Lomb Corp faces a challenging trading day as its stock slips significantly.
Bausch + Lomb Corp (BLCO.TO) is seeing a notable decline in its stock price today, down 2.60% to CA$22.10. This drop comes despite recent product launches and market developments that haven’t yet built investor confidence.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.09B
52W high
$25.70
52W low
$18.24
1W change
-3.75%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 15.0% over the next 12 months.
Consensus
Moderately BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.79
-15.0% Upside
Current Price
C$22.10
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
34.4%
Annualized
90-Day Vol
30.7%
Annualized
Trend (90d)
+11.0%
Annualized drift
90d Mean
C$22.98
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$22.39 | C$19.88 – C$25.22 |
| 60 trading days | C$22.69 | C$19.18 – C$26.84 |
| 90 trading days | C$22.98 | C$18.71 – C$28.24 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Bausch + Lomb's recent product introductions have not eased market concerns, leading to a significant stock decline today.
Bausch + Lomb Corp's stock down 2.60% today
The stock has dropped 4.8% year-to-date, contrasting sharply with the broader market's performance.
Bull case
Bausch + Lomb's recent launch of the EyeGility Inserter could strengthen its position in the ophthalmic surgical devices sector. This innovation may lead to improved sales and boost investor confidence over time.
Bear case
The current decline in stock price reflects broader investor skepticism, particularly as the company’s performance lags behind industry peers. This raises concerns about its growth trajectory.
Market Reaction to Recent Developments
Despite the recent launch of the EyeGility Inserter, aimed at streamlining cataract surgeries, Bausch + Lomb's stock is sliding today. The market seems to be reacting negatively, with shares down 3.3% since the announcement of the new product. This raises questions about whether these innovations are enough to drive sales or improve investor sentiment.
Comparative Performance and Investor Sentiment
Bausch + Lomb's stock has underperformed compared to its industry, with a year-to-date decline of 4.8% versus a modest 0.7% decline in the sector. This disparity highlights growing concerns among investors about the company's growth prospects and competitive positioning in the eye health market. The current sentiment is further compounded by the company's Zacks Rank of #4 (Sell), indicating a cautious outlook.
Advertisement
